HMTXF Stock, Hemostemix Information

Hemostemix Inc is a clinical-stage biotechnology company. The company's principal business activity is to develop, manufacture, and commercialize blood-derived cell therapies for medical conditions. Its technology platform for developing autologous cell therapies is for the treatment of vascular diseases. The group's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of critical limb ischemia.